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Nicotinic acetylcholine receptors (nAChRs) of the cerebral cortex and cerebellum of
rats were evaluated by a radioligand binding assay, employing tissue segments, or
homogenates as materials. [3H]-epibatidine speciﬁcally bound to nAChRs in rat cortex
or cerebellum, but the dissociation constants for [3H]-epibatidine differed between seg-
ments and homogenates (187 pM for segments and 42 pM for homogenates in the cortex
and 160 pM for segments and 84 pM for homogenates in the cerebellum). The abundance
of total nAChRs was approximately 310 fmol/mg protein in the segments of cortex and
170 fmol/mg protein in the segments of cerebellum, which were signiﬁcantly higher than
those estimated in the homogenates (115 fmol/mg protein in the homogenates of the
cortex and 76 fmol/mg protein in the homogenates of the cerebellum). Most of the [3H]-
epibatidine binding sites in the cortex segments (approximately 70% of the population)
showed high afﬁnity for nicotine (pK i = 7.9), dihydro-β-erythroidine, and cytisine, but the
binding sites in the cerebellum segments had slightly lower afﬁnity for nicotine (pK i = 7.1).
An upregulation of nAChRs by chronic administration of nicotine was observed in the cor-
tex segments but not in the cerebellum segments with [3H]-epibatidine as a ligand. The
upregulation in the cortex was caused by a speciﬁc increase in the high-afﬁnity sites for
nicotine (probably α4β2). The present study shows that the native environment of nAChRs
is important for a precise quantitative as well as qualitative estimation of nAChRs in rat
brain.
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INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) in the nervous system
are members of a family of ligand-gated ion channels, pentametric
in structure, with at least 11 different subunits (α2–α10 and β2–
β4) characterized (Lindstrom et al., 1996; Alexander et al., 2009).
Because different subunit compositions produce distinct nAChR
subtypes, the potential nAChR subtype diversity is vast (Lindstrom
et al., 1996).However, in general,α4β2 andα7 are the predominant
subtypes expressed in the central nervous system (CNS), whereas
the α3β4 subtype is the predominant subtype expressed in the
autonomic ganglia (Lindstrom, 2000; Alexander et al., 2009).
The nAChRs in the CNS are physiologically relevant in a wide
range of neuronal functions (such as cognition, motor control,
analgesia, and reward), and may be involved in pathological states
such as Alzheimer’s and Parkinson’s diseases (Grady et al., 2007;
Quik et al., 2007; Drever et al., 2010). Chronic nicotine exposure,
including smoking, is known to increase the number of nAChRs in
theCNSof rodents andhumans, although there is a region-speciﬁc
variation in the upregulation (Marks et al., 1992; Sanderson et al.,
1993;Davil-Garcia et al., 2003;Govind et al., 2009). Thus, smoking
seems to have certain therapeutic effects for Alzheimer’s disease,
although this conclusion is controversial (Hellstrom-Lindahl et al.,
2004; Connelly and Prentice, 2005; Picciotto and Zoli, 2008). In
addition,nAChRshave recently attracted attention as anovel target
of general anesthetics and antidepressants (McMorn et al., 1993;
Shytle et al., 2002; Tassonyi et al., 2002; Picciotto et al., 2008).
Identifying individual nAChR subtypes in the CNS has been
a difﬁcult task. The “high-afﬁnity agonist binding” α4β2 subtype
(labeled by [3H]-acetylcholine, [3H]-cytisine, (−)-[3H]-nicotine)
and the predominantly or entirely α7 subtype (labeled by [125I]-
?α-bungarotoxin) have been extensively characterized (Whiting
and Lindstrom, 1987; Schoepfer et al., 1990; Flores et al., 1992;
Picciotto et al., 1995; Orr-Urtreger et al., 1997; Marubio et al.,
1999). Subsequently, the discovery of epibatidine (an azabicyclo-
heptane alkaloid isolated from the skin of the Ecuadorian frog
Epipedobates tricolor) that binds to multiple nAChR subtypes with
high-afﬁnity provided a tool to identify novel nAChR subtypes
(Houghtling et al., 1995; Perry and Kellar, 1995; Marks et al.,
1998; Whiteaker et al., 2000; Grady et al., 2007). In the CNS of
rodents, the majority of high-afﬁnity [3H]-epibatidine binding
sites represent the α4β2 subtype, but the minority of the sites
were distinguished by their relatively low-afﬁnity for cytisine or
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dihydro-β-erythroidine in small nuclei dispersed across the brain
(Grady et al., 2007).
In most studies of nAChRs and other receptors in the CNS,
brain tissue was homogenized, and the resulting membrane or
particulate preparations have been exclusively used in the radioli-
gand binding assay (Bylund and Toews, 1993; Houghtling et al.,
1995; Yang et al., 1998; Marubio et al., 1999;Whiteaker et al., 2000;
Schneider and Michel, 2010). Although such a grind-and-bind
approach has been successfully used to identify receptor pharma-
cology for more than two decades, tissue homogenization may
cause alterations in receptor environments, resulting in different
properties from the inherent proﬁle in some receptors (Hiraizumi-
Hiraoka et al., 2004; Anisuzzaman et al., 2008, 2011; Morishima
et al., 2008). These recent studies suggest that the in situ envi-
ronment signiﬁcantly contributes to some receptor properties.
To avoid artiﬁcial modiﬁcation of the receptor environment as
much as possible, a binding assay for use with intact tissue seg-
ments and with physiological solution (such as Krebs solution)
was recently developed and has been demonstrated to be a pow-
erful method for detecting the inherent proﬁles of receptors in
a native manner (Tanaka et al., 2004; Muramatsu et al., 2005;
Yoshiki et al., 2009; Anisuzzaman et al., 2011). In contrast to the
conventional membrane binding assay, the tissue-segment bind-
ing assay is less prone to have a yield loss of receptors and to
have a modiﬁcation of the natural environment/conformation of
receptors,which may be caused during tissue homogenization and
membrane fractionation.
Previously,wedetected adifference in [3H]-epibatidinebinding
in the rat cerebral cortex between the tissue-segment binding assay
and the conventional membrane binding assay (Muramatsu et al.,
2005). In this study, we extensively evaluated [3H]-epibatidine
binding to nAChRs in the intact segments of rat cerebral cortex
and cerebellum, and compared the pharmacological proﬁles with
those in the homogenized preparations. Furthermore, the effects
on nAChRs of chronic nicotine administration were examined by
the tissue-segment binding assay.
MATERIALS AND METHODS
ANIMALS
Male Wistar rats weighing 250–350 g (SLC, Shizuoka, Japan) were
used.Thepresent studywasperformedaccording to theGuidelines
for Animal Experiments, University of Fukui (which is accred-
ited by the Ministry of Education, Culture, Sports, Science, and
Technology, Japan).
TISSUE-SEGMENT BINDING ASSAY
Rats were anesthetized with pentobarbital and killed by cervi-
cal dislocation. The brain was rapidly isolated and immersed in
modiﬁed Krebs–Henseleit solution containing: NaCl, 120.7 mM;
KCl, 5.9 mM; MgCl2, 1.2 mM; CaCl2, 2.0 mM; NaH2PO4, 1.2 mM;
NaHCO3,25.5 mM;andd-(+)-glucose,11.5 mM(pH= 7.4). This
solution had been oxygenated with a mixture of 95% O2 and 5%
CO2 andwas kept at 0˚C. The brainwas cleaned from the piamater
and substantia alba, and then the cerebral cortex and cerebellum
were cut into small pieces (approximately 2 mm× 2 mm× 1 mm).
The tissue-segment binding assay was performed at 4˚C for 26–
30 h, according to the method previously described (Muramatsu
et al., 2005; Anisuzzaman et al., 2011). Each segment of the
cortex or cerebellum was incubated in 0.5 ml of the modiﬁed
Krebs–Henseleit solution.
In saturation binding experiments, [3H]-epibatidine was used
at concentrations ranging from 30 to 2000 pM. In competition
experiments, 400 pM [3H]-epibatidine competed against various
concentrations of tested drugs. After incubation at 4˚C, tissue seg-
ments were quickly moved into a plastic tube containing 1.5 ml
of ice-cold (4˚C) modiﬁed Krebs–Henseleit solution and care-
fully washed by vortexing for 1 min. By this procedure, most of
the unbound radioligand was released from the segments into
the buffer medium and adsorbed to the plastic tube. The seg-
ments were then solubilized in 0.3 M NaOH solution to estimate
the bound radioactivity and protein content. Non-speciﬁc bind-
ing was determined in the presence of 100 μM nicotine. The
bound radioactivity was measured using a liquid scintillation
counter (Aloka, Tokyo, Japan). Protein concentration in each tis-
sue segment was measured by the Bio-Rad commercial protein
assay. Experiments were done in duplicate at each concentra-
tion of [3H]-epibatidine for binding saturation experiments or at
each concentration of competing ligand for competition binding
experiments.
HOMOGENATE BINDING ASSAY
As reported previously (Anisuzzaman et al., 2011), the rat cerebral
cortex and cerebellum were homogenized in 40 volumes (v/w;
for cortex) or 20 volumes (v/w; for cerebellum) of the modiﬁed
Krebs–Henseleit solution using a Polytron homogenizer at 4˚C.
The resulting homogenates were incubated with [3H]-epibatidine
in a ﬁnal volume of 0.5 ml modiﬁed Krebs–Henseleit solution
for 5 h at 4˚C. In competition experiments, 200 pM (for cortex)
and 300 pM (for cerebellum) of [3H]-epibatidine were used. Non-
speciﬁc binding of [3H]-epibatidine was determined with 100 μM
nicotine. The assay was terminated by rapid ﬁltration over What-
man GF/C ﬁlters presoaked with 0.3% polyethyleneimine using a
Brandel cell harvester and ﬁlters were rapidly washed with 5-ml
aliquots of ice-cold modiﬁed Krebs–Henseleit solution. The ﬁl-
ters were then dried and the radioactivity retained on the ﬁlter
paper was measured by liquid scintillation counting. The protein
contents of the homogenates were determined by the Bio-Rad
commercial protein assay.
CHRONIC ADMINISTRATION OF NICOTINE
Nicotine was administered for 3 weeks in drinking water. The con-
centration of nicotine in the drinking water was 50 μg/ml. The
control rats drank tap water during the experimental period. The
plasma concentration of nicotine after 3 weeks of oral nicotine
exposure was measured with high performance liquid chromatog-
raphy; theplasma levelwas 18± 3 ng/ml (n = 5),whichwas similar
to the nicotine concentrations (10–50 ng/ml) reported in smokers
(Benowitz et al., 1982; Pekonen et al., 1993).
After nicotine administration for 3 weeks, rats were killed and
the cortex or cerebellum segments were used in the binding
experiments, as described above.
DATA ANALYSIS
Binding data were analyzed using PRISM software (Version 5.01,
Graph Pad Software, La Jolla, CA, USA), as previously described
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(Muramatsu et al., 2005; Yoshiki et al., 2009). Brieﬂy, the data
from saturation binding studies were ﬁtted by a one-site satura-
tion binding isotherm and the K d values and the binding capacity
were then calculated. The abundance of the nAChRs is indicated as
the maximum binding capacity per milligram of total tissue pro-
tein (Bmax). For the competition studies, the data were analyzed
using the Binding-Competitive Equation of the PRISM software.
A two-site model was adopted only when the residual sums of
squares were signiﬁcantly less (P< 0.05) for a two-site ﬁt to the
data than for a one-site by F test comparison.
Data are represented as the mean± SEM with the number of
experiments (n). Results were considered to be signiﬁcant where
P values were less than 0.05 (Student’s t -test).
DRUGS
The following drugs were used in the present study: [5,6-
bicycloheptyl-3H]-epibatidine (speciﬁc activity, 2065 GBq/mmol;
PerkinElmer Life and Analytical Sciences, Boston, MA, USA);
1-quinuclidinyl-[phenyl-4-3H]-benzilate ([3H]-QNB; speciﬁc
activity, 1.81 TBq/mmol; GE Healthcare, Buckinghamshire, UK);
nicotine, nicotine tartrate dihydrate, and hexamethonium chlo-
ride (Nacalai Tesque, Kyoto, Japan); dihydro-β-erythroidine, cyti-
sine, and mecamylamine hydrochloride (Tocris Cookson Ltd.,
Bristol, UK); and α-bungarotoxin (Peptide Institute, Osaka,
Japan). For chronic administration of nicotine, aqueous nicotine
was used.
RESULTS
[3H]-EPIBATIDINE BINDING IN RAT CEREBRAL CORTEX AND
CEREBELLUM
The representative time courses of [3H]-epibatidine binding to
the intact segments (Figure 1A) and homogenate preparations
(Figure 1B) of rat cerebral cortex and to the intact segments
(Figure 2A) and homogenate preparations (Figure 2B) of rat
cerebellum are shown. At 4˚C, the binding to the segments was
extremely slow compared with that in the homogenates; therefore,
different incubation periods were applied in the segment binding
assay (26–30 h) and the homogenate binding assay (5 h). In the
saturation experiments, the speciﬁc binding of [3H]-epibatidine
to both the intact segments (Figure 1C) and homogenate prepa-
rations (Figure 1D) of rat cortex was saturable at the concen-
trations tested and ﬁtted a single-site model. However, the slopes
of the saturation curves were apparently different; the slope was
steeper for the homogenates than for the segments. Thus, the dis-
sociation constant (K d) for [
3H]-epibatidine was estimated to
be four times higher in the segment binding assay than in the
homogenate binding assay (Table 1). Furthermore, the maximum
binding capacity (Bmax) of [3H]-epibatidine was also approxi-
mately three times higher in the segments than in the homogenates
of rat cortex (Table 1). Differences in the time course, the den-
sity, and the dissociation constant for [3H]-epibatidine binding
were also observed between the segments and homogenates of rat
cerebellum (Figure 2 and Table 1). The afﬁnity for [3H]-QNB (a
FIGURE 1 |Time course and saturation isotherm of [3H]-epibatidine
binding in the intact segments (A,C) and homogenates (B,D) of rat
cerebral cortex.Time course (A,B): The intact segments were incubated
with 1000 pM [3H]-epibatidine at 4˚C for 1–24 h and the homogenates were
incubated with 500 pM [3H]-epibatidine at 4˚C for 15min to 5 h. Saturation
binding (C,D): The intact segments and homogenates were incubated with
[3H]-epibatidine (up to 2000 pM) at 4˚C for 28 h (segments) or 5 h
(homogenates). Speciﬁc binding (open circles) was determined by
subtracting the amount bound in the presence of 100μM nicotine
(asterisks) from total binding (closed squares). Each point represents the
mean of duplicate determinations. Each ﬁgure represents four to ﬁve
experiments.
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FIGURE 2 |Time course and saturation isotherm of [3H]-epibatidine
binding in the intact segments (A,C) and homogenates (B,D) of rat
cerebellum.Time course (A,B): The intact segments were incubated with
1000 pM [3H]-epibatidine at 4˚C for 1–24 h and the homogenates were
incubated with 500 pM [3H]-epibatidine at 4˚C for 15min to 5 h. Saturation
binding (C,D): The intact segments and homogenates were incubated with
[3H]-epibatidine (up to 2000 pM) at 4˚C for 28 h (segments) or 5 h
(homogenates). Speciﬁc binding (open circles) was determined by
subtracting the amount bound in the presence of 100μM nicotine
(asterisks) from total binding (closed squares). Each point represents the
mean of duplicate determinations. Each ﬁgure represents four to ﬁve
experiments.
Table 1 | Binding parameters of [3H]-epibatidine and [3H]-QNB in rat cortex and cerebellum.
Tissue Radioligand Segments Homogenates
K d(pM) Bmax K d(pM) Bmax
Cortex [3H]-epibatidine 187±20a 313±6a 42±10a 115±13a
(Nicotine-treated) (388±15)a,b (632±25)a,b (163±8)a,b (179±14)a,b
[3H]-QNB 1237±104a 2354±189 285±56a 2287±105
Cerebellum [3H]-epibatidine 160±34a 172±12a 84±3a 76±8a
Segment and homogenates binding experiments with [3H]-epibatidine and [3H]-QNB were conducted at 4˚C in the cortex and cerebellum of nicotine-untreated rats.
[3H]-epibatidine binding in the cortex of nicotine-treated rats was also represented in parenthesis.
Data represents mean±SEM of four to six experiments. Bmax: fmol/mg tissue protein.
aSigniﬁcantly different between segments and homogenates (P<0.05).
bSigniﬁcantly different from control and nicotine-treated rats (P<0.05).
muscarinic receptor ligand that was used as control) was also lower
in the cortex segments than in the homogenates, but the binding
capacity was not signiﬁcantly different between the segments and
the homogenates (Table 1).
Figures 1 and 2 further demonstrate that non-speciﬁc binding
of [3H]-epibatidine was signiﬁcantly higher in the segments than
in the homogenates. The non-speciﬁc binding in the segments was
rapidly equilibrated compared with speciﬁc binding (Figures 1A
and 2A) and increased lineally with increasing concentrations of
[3H]-epibatidine (Figures 1C and 2C). Because the non-speciﬁc
binding was insensitive to not only nicotine but also the other
tested ligands (see the competition experiments), it was consid-
ered that there was a signiﬁcant amount of non-nAChR sites in
the segments that were undetectable after homogenization.
Because the binding capacity and dissociation constant for
[3H]-epibatidine were signiﬁcantly different between tissue seg-
ments and homogenates, the pharmacological proﬁles of [3H]-
epibatidine binding sites in both preparations of rat cortex
were compared in competition binding experiments using vari-
ous drugs. Nicotine, dihydro-β-erythroidine, and cytisine showed
shallow competition curves in the segments of cortex and
approximately 70% of the speciﬁc binding sites were identiﬁed
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FIGURE 3 | Competition curves for various dugs at [3H]-epibatidine
binding sites in intact segments and homogenates of rat cerebral
cortex (A,B) and rat cerebellum (C,D). Intact segments (A,C) were
incubated with 400 pM [3H]-epibatidine for 28 h at 4˚C. Homogenates
were incubated with 200 pM [(B): cortex] or 300 pM [(D): cerebellum]
[3H]-epibatidine for 5 h at 4˚C. Each point represents the mean of
duplicate determinations. Each ﬁgure represents four to ﬁve
experiments.
as high-afﬁnity sites for these ligands (Figure 3A). In the
homogenates, dihydro-β-erythroidine and cytisine also showed
shallow curves, but the competition curve for nicotine better ﬁt-
ted a one-site model with a slightly higher pK i value than that
in the segments (Figure 3B and Table 2). Hexamethonium at
concentrations higher than 10μMwere competitive, butmecamy-
lamine (1 mM) and α-bungarotoxin (1–30 nM) failed to compete
in the [3H]-epibatidine binding assay with both segment and
homogenate preparations (Table 2). In general, the estimated lig-
and afﬁnities were higher in the homogenates compared with the
segments.
Because of the tissue limitation, the pharmacological proﬁle
at [3H]-epibatidine binding sites in the cerebellum was exam-
ined with nicotine and dihydro-β-erythroidine. Figure 3 shows
the competition curves in the segments (Figure 3C) and the
homogenates (Figure 3D) of rat cerebellum. Nicotine showed
biphasic competition in the homogenates (pKi= 8.2 and 6.3),
but competed for binding to the segments monotonically with an
intermediate afﬁnity (pKi= 7.1). These results are summarized in
Table 2.
EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON
[3H]-EPIBATIDINE BINDING SITES
Chronic administration of nicotine is known to cause an increase
in nAChRs in the brain, which is called upregulation. Because the
number of [3H]-epibatidine binding sites was underestimated in
homogenates as mentioned above, the nicotine-induced upregu-
lation was re-evaluated by the tissue-segment binding approach.
Administration of nicotine for 3 weeks increased the binding
density of [3H]-epibatidine with a slight decrease in afﬁnity
Table 2 | Pharmacological characteristics of [3H]-epibatidine binding
sites in rat cortex and cerebellum.
Drugs (selectivity) Segments Homogenates
pKihigh ( %) pKilow ( %) pKihigh ( %) pKilow %)
CORTEX
Nicotine 7.9±0.1 6.5±0.1 8.4±0.1
(α4β2> α4β4) (72%) (28%) (100%)
Dihydro-β-erythroidine 7.1±0.1 5.7±0.2 7.7±0.2 6.3±0.1
(α4β2, α4β4) (69%) (31%) (66%) (34%)
Mecamylamine NI NI
Cytisine 8.7±0.1 6.7±0.1 9.4±0.0 7.2±0.2
(α4β2, α4β4) (73%) (27%) (85%) (15%)
Hexamethonium 3.4±0.1 4.0±0.1
(100%) (100%)
α-Bungarotoxin NI NI
(α7, α9)
CEREBELLUM
Nicotine 7.1±0.2 8.2±0.1 6.3±0.1
(α4β2> α4β4) (100%) (68%) (32%)
Dihydro-β-erythroidine 7.4±0.3 5.1±0.3 7.1±0.1 4.6±0.2
(α4β2, α4β4) (70%) (30%) (67%) (33%)
%, Proportion of high or low-afﬁnity sites. Mean±SE of four to ﬁve rats. NI, no
inhibition.
Selectivity: subtype selectivity at concentrations around 10 nM.
in the rat cortex segments (Table 1). A similar tendency was
observed in the cortex homogenates, but the density and afﬁnity
were also signiﬁcantly different from the values estimated in the
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cortex segments of chronically nicotine-treated rats (Table 1).
The binding afﬁnities for nicotine in nicotine-treated rat cortex
(pKihigh and pKilow = 7.8± 0.2 and 6.3± 0.2 in the segments and
pKi= 8.1± 0.1 in the homogenates) were not signiﬁcantly differ-
ent from those in rats not treated with nicotine (Table 2). How-
ever, the proportion of nicotine-high-afﬁnity sites in the cortex
segments increased from 72% in control rats to 86% in nicotine-
treated rats (Figure 4). On the other hand, no upregulation was
caused by chronic nicotine administration in the cerebellum.
DISCUSSION
In the binding study with [3H]-epibatidine, the nAChRs in the
rat cerebral cortex and cerebellum were evaluated and compared
between the segments and the homogenates. Two major differ-
ences were observed in the present study. The ﬁrst is different
afﬁnities for [3H]-epibatidine and other nicotinic ligands between
the two preparations. Previous reports with particulate prepara-
tions of rat cortex showed an extremely high afﬁnity for [3H]-
epibatidine (K d = approximately 20 pM; Houghtling et al., 1995;
Marks et al., 1998). In the present study as well, such a high afﬁn-
ity for [3H]-epibatidine was estimated in the cortex homogenates
(K d = 42 pM), whereas the afﬁnity in the segments was signif-
icantly low (K d = 187 pM). Consistent with this difference in
afﬁnity, the binding time course of [3H]-epibatidine was faster
in the homogenates than in the segments.
It has been classically considered that antagonist afﬁnities are
constant for a given receptor subtype, regardless of the cell/tissue
background in which the receptor is expressed; this has been called
“antagonist assumption.” However, this traditional view has now
FIGURE 4 | Effects of chronic administration of nicotine for 3weeks.
The tissue segments or homogenates of the cerebral cortex and cerebellum
in nicotine-treated and untreated rats were incubated with [3H]-epibatidine
for 28 h (segments) or 5 h (homogenates) at 4˚C. The total density of
[3H]-epibatidine binding sites was estimated from saturation experiments in
the cortex and from 2nM [3H]-epibatidine binding in the cerebellum. From
the competition curves for nicotine, high-afﬁnity (open column), and
low-afﬁnity sites (hatched column) for nicotine were calculated in the
cerebral cortex. The binding sites in the cerebellum were not characterized
by nicotine and were represented as black columns. Control, rats not
treated with nicotine; nicotine, nicotine-treated rats. Mean±SEM of four
experiments. a: Signiﬁcantly different from those of the control rats.
been challenged by the observation of different pharmacologi-
cal antagonist proﬁles for the same gene product in different
cells/tissues (Kenakin, 2003; Baker and Hill, 2007; Nelson and
Challiss, 2007; Muramatsu et al., 2008; Nishimune et al., 2011).
The present results also suggest that the pharmacological prop-
erties of nAChRs are not necessarily constant, but rather may
be easily modiﬁed by assay conditions and probably by distinct
receptor environments.
In general, there is a tendency for antagonist afﬁnity to become
higher after homogenization, even though the other experimental
conditions were the same. The tendency was observed in the bind-
ing of [3H]-epibatidine to nAChRs (present study) and [3H]-QNB
or [3H]-N -methylscopolamine to muscarinic AChRs (present
results and the results of Anisuzzaman et al., 2011). Although
the precise mechanisms underlying the change in pharmacolog-
ical proﬁle by homogenization remain to be solved, intact tissue
can demonstrate distinct submembrane effector interactions in
the presence of constrained membrane architecture, which may
be easily destroyed by homogenization. In general, the relatively
universal high-afﬁnity obtained in the classical grind-and-bind
approach seems to be one of the bases of “antagonist assumption.”
The second difference observed in the present study is dis-
tinct densities of nAChRs estimated between segments and
homogenates. This is unique for nAChRs ([3H]-epibatidine
binding sites), because the abundance of muscarinic AChRs
([3H]-QNB binding sites) did not change after homogenization
(Table 1). However, it has been generally reported that homog-
enization causes a yield loss of receptors (Colucci et al., 1981;
Kwan et al., 1981; Faber et al., 2001; Tanaka et al., 2004; Su et al.,
2008). The density of [3H]-epibatidine binding sites estimated
in the present segment study with rat cortex (313 fmol/mg tissue
protein) is greater than the estimates reported previously in con-
ventionalmembrane binding assayswith rat cortex (5–83 fmol/mg
of membrane protein; Houghtling et al., 1995; Flores et al., 1997;
Davil-Garcia et al., 2003) and with mouse cortex (54.9 fmol/mg
of membrane protein; Marks et al., 1998). Previously, we showed
that the protein yield of crude membrane preparations in rat cor-
tex after simple centrifugation or fractionation was approximately
50% of the total tissue protein (Morishima et al., 2008). Therefore,
it seems that the density of nAChRs estimated previously in the
concentrated membrane preparations may be much lower, if the
values were adjusted at the same denominator level (that is, per
mg of “total tissue protein”).
As mentioned above, the present study reveals that intact
tissue conditions or the native physiological environment are
very important in the quantitative and qualitative evaluation of
nAChRs. However, we are not neglecting the classical grind-
and-bind approach and recognize its successful and signiﬁ-
cant contribution to receptor pharmacology over the past two
decades. Indeed, the present competition study with segments
and homogenates clearly shows high- and low-afﬁnity sites for
dihydro-β-erythroidine and cytisine in the [3H]-epibatidine bind-
ing sites, which is consistent with the previous results obtained in
membrane binding studies (Whiteaker et al., 2000; Grady et al.,
2007). The high-afﬁnity sites in the cortex are major in propor-
tion and seem to correspond to α4β2 and/or α4β4, as reported
previously.
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In the segments, the [3H]-epibatidine binding sites were com-
posed of high- and low-afﬁnity sites for nicotine in the cortex
but a single afﬁnity site in the cerebellum. It is interesting to
note that the high afﬁnity for nicotine in the cortex (pKi= 7.9)
was slightly higher than the afﬁnity in the cerebellum (pKi= 7.1).
Because plasma concentrations of nicotine are reported to be 10–
50 ng/ml in nicotine-treated rats and in smokers (present study;
Benowitz et al., 1982; Pekonen et al., 1993), the high-afﬁnity
sites for nicotine in the cortex may mainly contribute to the
upregulation, as shown in Figure 4. The extent of upregulation
estimated in the cortex segments (nearly 100%) was greater than
those reported in previous membrane binding studies and in the
present data of homogenate binding (approximately 50%). On
the other hand, no upregulation was observed in the cerebellum
in the present segment binding assay aswell as previousmembrane
binding assays (Marks et al., 1992; Flores et al., 1997; Pietila
et al., 1998), conﬁrming regional variation of the nicotine-induced
upregulation.
In summary, the present comparative binding study with tissue
segments and homogenates shows that the native conformation
and inherent properties of nAChRs are strongly modiﬁed by the
receptor environment and suggests that keeping intact tissue con-
ditions in the assays is important for determining the properties
of nAChRs and probably other receptors.
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